DOCSLIB.ORG

The Pharmacologist March

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Vol. 55 Number 1 2013 The Pharmacologist March Boston... Here we come! In this issue: • 2013 Award Winners • Election Results • AZT: A Rational Drug Ahead of its Time, by Rebecca J. Anderson, Ph.D. • 2012 P.B. Dews Award Lecture, by James E. Barrett, Ph.D. • International Collaboration article, by John S. Lazo, Ph.D. and Philip Routledge, M.D. Vacancy ASPETAnnouncement Execu ve Offi cer The American Society for Pharmacology and Experimental Therapeutics (ASPET) invites applications from dy- namic and dedicated individuals seeking to ill the position of Executive Oficer with service beginning as soon as August 1, 2013. ASPET is a non-proit scientiic society with more than 5,000 members who are employed in academia, industry, foundations and the government, or are students and postdoctoral fellows. ASPET members are active in a wide array of activities including conducting basic and clinical pharmacological re- search designed to develop new medicines and therapeutic agents that ight existing and emerging diseases, as well as educating the next generation of pharmacologists and other health professionals. ASPET is located in Bethesda, Maryland on the campus of the Federation of American Societies for Experimental Biology (FASEB), of which ASPET is a founding member. The Executive Oficer reports directly to the ASPET Council and is responsible for implementing inancial, scientiic, publication, membership, educational, and other programs and policies approved by the Board. The responsibilities of the individual in this position include but are not limited to the following: • Oversees all operations, programs and initiatives of ASPET including managing an ofice of 14 staff who carry out the day-to-day activities of ASPET • Works closely with the Director of Accounting, Membership and Subscriber Services, senior ASPET staff, the Treasurer and the Finance Committee, which are responsible for the inancial operations of the ASPET to develop and maintain the budget • Interacts with and supervises the Publications Director and staff to ensure eficient publication of ASPET’s journals, the Government and Public Affairs oficer to promote advocacy activities, and the Director of Marketing to promote the society through the use of the website and social media • Develops new programs and initiatives in conjunction with the ASPET Council and directs outreach, fundraising, and educational programs • Is responsible for ASPET's scientiic meetings and coordinates activities of all ASPET Council meetings committees, Divisions and all committees. • Represents ASPET in public and private venues Qualiied candidates should have a record of achievement and leadership in academic, industrial, governmen- tal, association and/or other not-for-proit organizations, prior executive/administrative experience, and a demonstrated ability to conceptualize and implement new projects. An advanced degree in science and knowl- edge of pharmacology are highly preferred. Excellent communication, interpersonal and management skills are required. Please send a letter of application, including a statement of interest and a résumé or curriculum vitae by April 12, 2013 to FASEB/ASPET Human Resources 9650 Rockville Pike, Bethesda, MD 20814 or email materials to [email protected]. Please visit our website at http://www.aspet.org for more information about ASPET. The Pharmacologist 2 Volume 55 Number 1, 2013 President's Corner Comings and Goings Dear ASPET Members, We are fast approaching the 2013 ASPET Annual Mee ng, which will be held in Boston at Experimental Biology 2013 on April 20-24. This year, we are also mee ng with the Bri sh Pharmacological Society, the premier pharmacology society in the U.K. formed in 1931. We have an excit- ing program planned which you will not want to miss: the Sir James Black Lecture features 2012 Nobel Laureate in Chemistry Robert Le owitz, the Julius Axelrod Award Lecture by Gavril W. Pasternak speaking on "No pain, big gain: Truncated mu opioid receptor splice variants as drug targets," and the John J. Abel Award lecture given by Arthur Christopoulos, "Reciprocal rela onships: The yin and yang of GPCR allostery." We have fabulous sessions that should be a rac ve to students, postdoctoral fellows, academic faculty, and scien sts in biotechnology and pharmaceu cal organiza on. For our students and fellows, we have a Graduate Student Colloquium on "Introducing the Individual Devel- opment Plan: A key to success," a symposium on "Transla ng pharmacology into career choices in the pharmaceu cal and biotechnology industry," and a workshop on the "Art of item wri ng (NBME style) and basics of assessment." There are many symposia, including ones on "Cogni ve enhancers for the treatment of neuropsychiatric disorders," "Emerging technologies for delivering neurotherapeu cs across the blood-brain barrier," "Epigene c control of drug metabolism and transport," "Transcrip on factors as therapeu c drug targets," sleep apnea, apolipoprotein E, stem cells, and systems pharmacology. There will be numerous opportuni es for you to meet old friends and make new ones. I hope to see you at our Annual Mee ng at EB 2013. Some of you may know that our Execu ve Offi cer for the last 16 years, Chris e Carrico, has decided to re re later this year. Chris e truly has made an indelible mark on our society, recrui ng and maintaining a remarkable staff in the main offi ce and helping to build it into the pre- mier pharmacological organiza on in the world. She has been the heart and soul of ASPET, overseeing our fi nancial and educa on mission, ensuring members of Council, the Board of Publica on Trustees, divisions, and commi ees fulfi ll their responsibili es in a mely manner. Her outstanding professionalism places ASPET in a fabulous posi on to move forward na onally and interna onally during this exci ng me in pharmacology. We have iden fi ed a search commi ee that will begin the process of iden fying our next Execu ve Offi cer. As we proceed, I hope to provide you with addi onal informa on about our progress. Please feel free to communicate any advice or names of candidates to Rick Neubig ([email protected]) or me ([email protected]). I also hope you will join me in celebra ng Chris e's many accomplishments at our mee ng in Boston. Sincerely, John S. Lazo The Pharmacologist 3 Volume 55 Number 1, 2013 The Pharmacologist is published and distributed by the American Society for Pharmacology and Experimental Contents Therapeu cs. NEWS EDITOR President's Corner 3 Gary Axelrod 2013 Elec on Results 5 EDITORIAL ADVISORY BOARD Stephen M. Lanier, PhD 2013 ASPET Award Winners 6 Charles P. France, PhD ASPET Annual Mee ng at EB 2013 Kenneth E. Thummel, PhD Important Dates and Informa on 10 COUNCIL Proposed Bylaws Change 10 President John S. Lazo, PhD Full Program 12 President-Elect Ac vi es for Students & Postdocs 27 Richard R. Neubig, MD, PhD 4th GPCR Colloquium 28 Past President Lynn Wecker, PhD FEATURES Secretary/Treasurer Interna onal Collabora on 30 Edward T. Morgan, PhD by John S. Lazo, Ph.D. and Philip Routledge, M.D. Secretary/Treasurer-Elect AZT: A Ra onal Drug Ahead of its Time 31 Sandra P. Welch, PhD by Rebecca J. Anderson, Ph.D. Past Secretary/Treasurer Mary E. Vore, PhD 2012 P.B. Dews Lecture 35 Councilors given by James E. BarreƩ , Ph.D. Charles P. France, PhD DEPARTMENTS Stephen M. Lanier, PhD In Sympathy 45 Kenneth E. Thummel, PhD Chair, Board of Publica ons Trustees Obituary: Peter Dews 45 James E. Barre , PhD wriƩ en by W.H. Morse Chair, Program Commi ee Journals 49 Sco Waldman, MD, PhD Science Policy 51 FASEB Board Representa ve Book Review: State of Wonder by Ann Patche , 54 Brian M. Cox, PhD reviewed by ChrisƟ ne K. Carrico, Ph.D. Execu ve Offi cer Chris ne K. Carrico, PhD In the Spotlight: Interviews with ASPET Members 55 The Pharmacologist (ISSN 0031-7004) is published quarterly in Members in the News 58 March, June, September, and December by the American Society Staff News 59for Pharmacology and Experimental Therapeu cs, 9650 Rockville Pike, Bethesda, MD 20814-3995. Annual subscip on rates: New ASPET Members 60 $20.00 for ASPET members; $45.00 for U.S. nonmembers and Division News and Elec on Results ins tu ons; $70.00 for nonmembers and ins tu ons outside the U.S. Single copy: $20.00. Copyright © 2013 by the American Behavioral Pharmacology 62 Society for Pharmacology and Experimental Therapeu cs Inc. All Cardiovascular Pharmacology 63 rights reserved. Periodicals postage paid at Bethesda, MD. GST number for Canadian subscribers: BN:13489 2330 RT. Drug Metabolism 64 ASPET assumes no responsibility for the statements and Integra ve Systems, Transla onal and Clinical Pharmacology 64 opinions advanced by contributors to The Pharmacologist. Molecular Pharmacology 66 Deadlines for submission of material for publica on: Issue 1, Neuropharmacology 66 February 15; Issue 2, May 8; Issue 3, August 6; and Issue 4, November 5. Toxicology 67 Postmaster: Send address changes to: The Pharmacologist, Chapter News ASPET, 9650 Rockville Pike, Bethesda, MD 20814-3995. Upstate New York Pharmacology Society 68 Great Lakes 68 Mid-Atlan c Pharmacology Society 69 2013 Dues Notices Membership Informa on 71 If you haven‛t already done so, please Membership Applica on 72 pay your 2013 dues. You can mail in APPENDIX (ONLINE ONLY) your payment or renew online at: MAPS 2012 Annual Mee ng Abstracts A-1 https://www.aspet.org/login.aspx. The Pharmacologist 4 Volume 55 Number 1, 2013 2013 Election Results ASPET is pleased to announce the following elec on winners: PRESIDENT-ELECT Anne e E. Fleckenstein, Ph.D. Dr. Fleckenstein joined ASPET as a Student Member in 1993 and has been a Regular Member since 1996. As a student mem- ber, she received several travel awards including in 1998 a James A.
Recommended publications
  • 2004 Albert Lasker Nomination Form

    2004 Albert Lasker Nomination Form

    albert and mary lasker foundation 110 East 42nd Street Suite 1300 New York, ny 10017 November 3, 2003 tel 212 286-0222 fax 212 286-0924 Greetings: www.laskerfoundation.org james w. fordyce On behalf of the Albert and Mary Lasker Foundation, I invite you to submit a nomination Chairman neen hunt, ed.d. for the 2004 Albert Lasker Medical Research Awards. President mrs. anne b. fordyce The Awards will be offered in three categories: Basic Medical Research, Clinical Medical Vice President Research, and Special Achievement in Medical Science. This is the 59th year of these christopher w. brody Treasurer awards. Since the program was first established in 1944, 68 Lasker Laureates have later w. michael brown Secretary won Nobel Prizes. Additional information on previous Lasker Laureates can be found jordan u. gutterman, m.d. online at our web site http://www.laskerfoundation.org. Representative Albert Lasker Medical Research Awards Program Nominations that have been made in previous years may be updated and resubmitted in purnell w. choppin, m.d. accordance with the instructions on page 2 of this nomination booklet. daniel e. koshland, jr., ph.d. mrs. william mccormick blair, jr. the honorable mark o. hatfied Nominations should be received by the Foundation no later than February 2, 2004. Directors Emeritus A distinguished panel of jurors will select the scientists to be honored. The 2004 Albert Lasker Medical Research Awards will be presented at a luncheon ceremony given by the Foundation in New York City on Friday, October 1, 2004. Sincerely, Joseph L. Goldstein, M.D. Chairman, Awards Jury Albert Lasker Medical Research Awards ALBERT LASKER MEDICAL2004 RESEARCH AWARDS PURPOSE AND DESCRIPTION OF THE AWARDS The major purpose of these Awards is to recognize and honor individuals who have made signifi- cant contributions in basic or clinical research in diseases that are the main cause of death and disability.
  • A Review of J. Craig Venter's a Life Decoded

    A Review of J. Craig Venter's a Life Decoded

    A peer-reviewed electronic journal published by the Institute for Ethics and Emerging Technologies ISSN 1541-0099 17(1) – March 2008 A review of J. Craig Venter’s A Life Decoded Randy Mayes, Duke University Journal of Evolution and Technology - Vol. 17 Issue 1 – March 2008 - pgs 71-72 http://jetpress.org/v17/mayes.htm In the early 1980s, a number of researchers suggested sequencing and mapping the human genome to help the science community better understand diseases and evolution. Following the announcement that the human genome had been sequenced, scientists wrote in peer-reviewed journals that we are not as hardwired as was once believed, and that the sequencing of the genome was just the beginning. Today, researchers have a new set of goals. In popular journalism, however, the science was lost in the shuffle. The media focused more on the dynamics of the conflicting philosophies of the private and public projects. This emphasis is also clear in the titles of several books chronicling the Human Genome Project, all appearing prior to the recent release of Craig Venter’s autobiography, A Life Decoded: My Genome: My Life (2007). Readers will find that Robert Cook-Deegan’s The Gene Wars (1995) and The Common Thread by Sir John Sulston and Georgina Ferry (2002), both written by insiders, are biased towards the philosophy of the public project, a commons approach. Sulston is a socialist who grows runner beans and drives a second hand car. By contrast, Venter travels in Lear jets and conducts business from his yacht. Three other books are more objective.
  • Award Recipients Award Consists of a Plaque and a Cash Stipend

    Award Recipients Award Consists of a Plaque and a Cash Stipend

    SOT HONOR AND AWARD DESCRIPTIONS AND HISTORY In recognition of distinguished toxicologists and students, Nominations for many awards must be submitted by a sponsor SOT presents Honorary Membership and Awards each year. and a seconder who are Full members of SOT using the online In addition to receiving a plaque, recipients are honored Award Nomination form. The supporting documentation at a special Awards Ceremony at the SOT Annual Meeting must indicate the candidate’s achievements in toxicology and and their names are listed in SOT publications. The deadline is critical in the review of each application. See the award for 2013 Honorary Membership and Award nominations is description for the additional requirements and details. There October 9, 2012. are specific applications for Fellowships and Graduate Student Travel Support. SOT Council reviews nominations for Honorary Membership and the Awards Committee reviews applications for SOT Other graduate student and postdoctoral fellow awards are Awards and most Sponsored Awards. Awards Committee available through Regional Chapters, Special Interest Groups, members are not eligible to receive any awards conferred by and Specialty Sections (many of these awards are funded the Committee while serving on the Committee and for one through the various Named Endowment Funds). A student or subsequent year. postdoctoral scholar may apply for any award for which he or she is eligible and may apply for and receive multiple awards, The Best Paper Awards in Toxicological Sciences are reviewed whether SOT, Regional Chapters, Special Interest Groups, or by the Board of Publications. The Education Committee selects Specialty Sections administrators the awards. Policies related the recipients of the Pfizer Undergraduate Travel Award and to travel support are determined by the sponsor (SOT, the Committee on Diversity Initiatives selects the recipients Regional Chapter, Special Interest Group, or Specialty Section).
  • (R&D) Tax Credit

    (R&D) Tax Credit

    Report toThe the Pennsylvania Pennsylvania Department of General Revenue Assembly Bureau of Research on the Research and Development (R&D) Tax Credit The Pennsylvania Department of Revenue Bureau of Research March 15, 2012 Pennsylvania Research and Development Tax Credit Page 1 of 14 The Pennsylvania R&D Tax Credit Statute On May 7, 1997, Act 7 of 1997 created the Pennsylvania research and development (R&D) tax credit. The R&D tax credit provision became Article XVII-B of the Tax Reform Code of 1971 (TRC). The intent of the R&D tax credit was to encourage taxpayers to increase R&D expenditures within the Commonwealth in order to enhance economic growth. The terms and concepts used in the calculation of the Commonwealth’s R&D tax credit are based on the federal government’s R&D tax credit definitions for qualified research expense.1 For R&D tax credits awarded between December 1997 and December 2003, Act 7 of 1997 authorized the Department of Revenue (Department) to approve up to $15 million in total tax credits per fiscal year. Additionally, $3 million of the $15 million was set aside for “small” businesses, where a “small business” is defined as a “for-profit corporation, limited liability company, partnership or proprietorship with net book value of assets totaling…less than five million dollars ($5,000,000).” Over the years, several changes have been made to the R&D tax credit statute. Table 1 lists all of the acts that have changed the R&D tax credit statute, along with the applicable award years, the overall tax credit cap and the “small” business set aside.
  • February 19, 2014

    February 19, 2014

    CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS Oversight Committee Meeting February 19, 2014 CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS Summary Overview of the February 19, 2014, Oversight Committee Meeting Please find enclosed the meeting packet for the next meeting of the CPRIT Oversight Committee to be held on Wednesday, February 19, 2014, at 10:00 AM. This summary overview of major agenda items provides background on key issues for Committee consideration. CEO Report Wayne Roberts will present the CEO’s report and address issues assigned by the Oversight Committee at the January 24th meeting including reconstituting the University Advisory Committee (UAC) and proposed dashboard metrics for the agency. Chief Scientific Officer Program Portfolio Presentation and Grant Award Recommendations Dr. Margaret Kripke will present the Program Integration Committee’s recommendations for scientific research awards. The research continuation grant recommendations are the first grant applications to be considered under the “new” review process set out by SB 149. SB 149 changed the way that grant recommendations are formally approved. A vote by two-thirds of the Oversight Committee that are present and voting (i.e. not recused because of a conflict of interest) is required to approve each funding recommendation. If two-thirds of the Oversight Committee does not vote to approve an award recommendation, then a statement explaining the reason for not following the PIC’s recommendation must be included in the meeting minutes. Product Development Officer Program Portfolio Presentation and Grant Award Recommendations Kristen Doyle, acting Product Development Officer, and Dr. Jack Geltosky, CPRIT’s Product Development Review Council Chair, will discuss CPRIT’s product development portfolio and present the Chief Executive Officer’s recommendations for product development grant awards.
  • DOE Human Genome Program Contractor-Grantee Workshop III

    DOE Human Genome Program Contractor-Grantee Workshop III

    ORNL/M-2588 uman enome Program U.S. Department of Energy Contractor-Grantee Workshop III February 7-10, 1993 Santa Fe, New Mexico Date Published: January 1993 Prepared for the U.S. Department of Energy Office of Energy Research Office of Health and Environmental Research Washington, D.C. 20585 under budget and reporting code KP 0404000 Prepared by Human Genome Management Information System Oak Ridge National Laboratory Oak Ridge, TN 37831-6050 Managed by MARTIN MARIETTA ENERGY SYSTEMS, INC. for the U.S. DEPARTMENT OF ENERGY UNDER CONTRACT DE-AC05-840R21400 ., Contents Workshop Agenda v-vii Poster Presentation Times viii Introduction To The Santa Fe Workshop ix Abstracts* U.S. Department of Energy Laboratories Human Genome Centers LANL-Los Alamos National Laboratory (1-20) LBL-Lawrence Berkeley Laboratory (21-48) LLNL-Lawrence Livermore National Laboratory (49-75) Ames Research Center (76) ANL-Argonne National Laboratory (77-80) BNL-Brookhaven National Laboratory (81) LANL-Los Alamos National Laboratory (82-90) LBL-Lawrence Berkeley Laboratory (91-96) ORNL-Oak Ridge National Laboratory (97-109) PNL-Pacific Northwest Laboratory (110-111) Other Institutions (112-198) Appendices A. Subject Index 199 B. Author Index 200 C. Anticipated Workshop Attendees 207 'Each section alphabetized by first author. iii Workshop Agenda DOE Human Genome Program Contractor-Grantee Workshop ill Santa Fe, NM February 7-10, 1993 Plenary sessions are in the Eldorado, poster sessions are in the Hilton. Each speaker and demonstration in the plenary sessions will have an abstract number, and thus a poster, associated with the talk. Schedule correct as of January 15, 1993.
  • Case Study: Leroy Hood / February 10, 2021

    Case Study: Leroy Hood / February 10, 2021

    Case Study: Leroy Hood / February 10, 2021 CASE STUDY: LEROY HOOD Introduction Leroy Hood is an inventor, entrepreneur, and in the vanguard of molecular biotechnology and genomics. He co-founded systems biology: an interdisciplinary, holistic approach to biomedical research that focuses on how molecules operate together. His inventions include the gas liquid phase protein sequencer, protein synthesizer, DNA sequencer, DNA synthesizer, the ink-jet-based DNA synthesizer (large-scale DNA synthesis) and the nanostring technology for single-molecule DNA and RNA analyses. Taken together, these six instruments have formed the technological foundation for much of the research conducted in the biotechnology- and genomics-related fields today. Hood received the Lemelson- MIT Prize in 2003 for his revolutionary innovations, which led to new, comprehensive knowledge of the factors that contribute to human disease and Leroy Hood (Photo/Dale DeGabriele) wellness. Background and Early Life Born between mountain ranges in Missoula, Montana, Leroy Hood cultivated an early fascination with the natural world and a lifelong affinity for physical fitness. He spent much of his childhood at his grandfather’s ranch in the Beartooth Mountains, and his family encouraged exploration, independence and excellence in all endeavors. Hood’s interest in biology began with the birth of his younger brother who was diagnosed with Down syndrome. At the time, the scientific community had no way of explaining why some babies were born with this condition, and Hood’s curiosity about biological conundrums and the human complexities they dictated began to grow. Hood’s family moved to Shelby, Montana, at the start of his high school career.
  • Drug Repositioning: Extracting Added Value from Prior R&D Investments

    Drug Repositioning: Extracting Added Value from Prior R&D Investments

    Drug Repositioning: Extracting Added Value from Prior R&D Investments Hermann A.M. Mucke, Ph.D. InsightPharmaReports.com Drug Repositioning: Extracting Added Value from Prior R&D Investments Hermann A.M. Mucke, Ph.D. Published in July 2010 by Cambridge Healthtech Institute • www.InsightPharmaReports.com • Reproduction prohibited i Insight Pharma Reports is a division of Cambridge Healthtech Institute, a world leader in life science information and analysis through conferences, research reports, and targeted publications. Insight Pharma Reports focus on pharmaceutical R&D—the technologies, the companies, the markets, and the strategic business impacts. They regularly feature interviews with key opinion leaders; surveys of the activities, views, and plans of individuals in industry and nonprofit research; and substantive assessments of technologies and markets. Managers at the top 50 pharma companies, the top 100 biopharma companies, and the top 50 vendors of tools and services rely on Insight Pharma Reports as a trusted source of balanced and timely information. Related Report Data Mining in Drug Development and Translational Medicine by Hermann A.M. Mucke, Ph.D. General Manager: Alfred R. Doig, Jr. 781-972-1348, [email protected] Editorial Operations Director: Laurie Sullivan 781-972-1353, [email protected] Design Director: Tom Norton 781-972-5440, [email protected] Production Director: Ann Handy 781-972-5493, [email protected] Marketing Manager: James Prudhomme 781-972-5486, [email protected] Customer Service: Rose LaRaia 781-972-5444, [email protected] Corporate Subscriptions: David Cunningham 781-972-5472, [email protected] Global Report Sales: Jack Valeri 781-972-1355, [email protected] Insight Pharma Reports, 250 First Ave., Suite 300, Needham, MA 02494 www.InsightPharmaReports.com ii • www.InsightPharmaReports.com • Reproduction prohibited Drug Repositioning: Extracting Added Value from Prior R&D Investments Hermann A.M.
  • Research Organizations and Major Discoveries in Twentieth-Century Science: a Case Study of Excellence in Biomedical Research

    Research Organizations and Major Discoveries in Twentieth-Century Science: a Case Study of Excellence in Biomedical Research

    A Service of Leibniz-Informationszentrum econstor Wirtschaft Leibniz Information Centre Make Your Publications Visible. zbw for Economics Hollingsworth, Joseph Rogers Working Paper Research organizations and major discoveries in twentieth-century science: A case study of excellence in biomedical research WZB Discussion Paper, No. P 02-003 Provided in Cooperation with: WZB Berlin Social Science Center Suggested Citation: Hollingsworth, Joseph Rogers (2002) : Research organizations and major discoveries in twentieth-century science: A case study of excellence in biomedical research, WZB Discussion Paper, No. P 02-003, Wissenschaftszentrum Berlin für Sozialforschung (WZB), Berlin This Version is available at: http://hdl.handle.net/10419/50229 Standard-Nutzungsbedingungen: Terms of use: Die Dokumente auf EconStor dürfen zu eigenen wissenschaftlichen Documents in EconStor may be saved and copied for your Zwecken und zum Privatgebrauch gespeichert und kopiert werden. personal and scholarly purposes. Sie dürfen die Dokumente nicht für öffentliche oder kommerzielle You are not to copy documents for public or commercial Zwecke vervielfältigen, öffentlich ausstellen, öffentlich zugänglich purposes, to exhibit the documents publicly, to make them machen, vertreiben oder anderweitig nutzen. publicly available on the internet, or to distribute or otherwise use the documents in public. Sofern die Verfasser die Dokumente unter Open-Content-Lizenzen (insbesondere CC-Lizenzen) zur Verfügung gestellt haben sollten, If the documents have been made available under an Open gelten abweichend von diesen Nutzungsbedingungen die in der dort Content Licence (especially Creative Commons Licences), you genannten Lizenz gewährten Nutzungsrechte. may exercise further usage rights as specified in the indicated licence. www.econstor.eu P 02 – 003 RESEARCH ORGANIZATIONS AND MAJOR DISCOVERIES IN TWENTIETH-CENTURY SCIENCE: A CASE STUDY OF EXCELLENCE IN BIOMEDICAL RESEARCH J.
  • Bacterial Artificial Chromosomes (Bacs) Became the Most Broadly Used Resource for Several Reasons

    Bacterial Artificial Chromosomes (Bacs) Became the Most Broadly Used Resource for Several Reasons

    Bacterial Artificial Chromosomes STC Production on Human BACs Archive Provided for Historical Purposes Home STC Project History 1995 Meeting Articles Contacts Links HGP Sequences HGP Research Several types of DNA library resources were sponsored by the DOE before and during the Human Genome Program (HGP). These included both prokaryotic and eukaryotic vector systems, and clone libraries representing single chromosomes. Bacterial Artificial Chromosomes (BACs) became the most broadly used resource for several reasons. The large size was a good match for capabilities of high throughput sequencing centers. As contrasted to some earlier resources, chimerism (having gene segments from multiple chromosome sites combined in one clone) is substantially if not completely absent. With some interesting exceptions , the BACS are stable in their bacterial hosts. In support of the functional analysis of genes, the BACs are very useful for making transgenic animals with segments of human DNAs. A brief history of BAC development is available in a preface to a 2003 issue of Methods in Molecular Biology , wherein details of BAC related protocols reside. One particular BAC project was crucial to the timely completion of human genome sequencing. (See history .) In a 1996 initiative, the DOE Office of Biological and Environmental Research sponsored the production of sequence tag connectors (STCs) for the BACs being used in human genome sequencing. (STCs are sequence reads at the ends of cloned DNA segments; they mark the boundaries of the cloned DNA.) This publicly available resource has served both the international public collaboration and Celera Genomics Inc . in the generation of the human genome sequence. The BACs representing a genome can together serve as a scaffold on which much shorter DNA sequence assemblies can be located.
  • Lasker Interactive Research Nom'18.Indd

    Lasker Interactive Research Nom'18.Indd

    THE 2018 LASKER MEDICAL RESEARCH AWARDS Nomination Packet albert and mary lasker foundation November 1, 2017 Greetings: On behalf of the Albert and Mary Lasker Foundation, I invite you to submit a nomination for the 2018 Lasker Medical Research Awards. Since 1945, the Lasker Awards have recognized the contributions of scientists, physicians, and public citizens who have made major advances in the understanding, diagnosis, treatment, cure, and prevention of disease. The Medical Research Awards will be offered in three categories in 2018: Basic Research, Clinical Research, and Special Achievement. The Lasker Foundation seeks nominations of outstanding scientists; nominations of women and minorities are encouraged. Nominations that have been made in previous years are not automatically reconsidered. Please see the Nomination Requirements section of this booklet for instructions on updating and resubmitting a nomination. The Foundation accepts electronic submissions. For information on submitting an electronic nomination, please visit www.laskerfoundation.org. Lasker Awards often presage future recognition of the Nobel committee, and they have become known popularly as “America’s Nobels.” Eighty-seven Lasker laureates have received the Nobel Prize, including 40 in the last three decades. Additional information on the Awards Program and on Lasker laureates can be found on our website, www.laskerfoundation.org. A distinguished panel of jurors will select the scientists to be honored with Lasker Medical Research Awards. The 2018 Awards will
  • (R&D) Tax Credit

    (R&D) Tax Credit

    Report to theThe Pennsylvania Pennsylvania Department General of Revenue Assembly Bureau of Research on the Research and Development (R&D) Tax Credit The Pennsylvania Department of Revenue Bureau of Research March 15, 2010 Pennsylvania Research and Development Tax Credit Page 1 of 15 The Pennsylvania R&D Tax Credit Statute As part of the Fiscal Year 2009-10 budget, Act 48 of 2009 reduced the amount of tax credits available under several tax credit programs that can be awarded during the following two years. Act 48 reduced the total amount of R&D tax credit available in FY 2009-10 from $40 million to $20 million and in FY 2010-11 from $40 million to $18 million. Starting in FY 2011-12, the total amount of R&D tax credit the Department can award returns to $40 million per year. ******** On May 7, 1997, Act 7 of 1997 created the Pennsylvania research and development (R&D) tax credit. The R&D tax credit provision became Article XVII-B of the Tax Reform Code of 1971 (TRC). The intent of the R&D tax credit was to encourage taxpayers to increase R&D expenditures within the Commonwealth in order to enhance economic growth. The terms and concepts used in the calculation of the Commonwealth’s R&D tax credit are based on the federal government’s R&D tax credit definitions for qualified research expense.1 Over the years, several changes have been made to the R&D tax credit statute. On December 23, 2003, Governor Edward G. Rendell signed Act 46 of 2003 into law.